These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

203 related items for PubMed ID: 29939487

  • 1. Amiloride resolves resistant edema and hypertension in a patient with nephrotic syndrome; a case report.
    Hinrichs GR, Mortensen LA, Jensen BL, Bistrup C.
    Physiol Rep; 2018 Jun; 6(12):e13743. PubMed ID: 29939487
    [Abstract] [Full Text] [Related]

  • 2. Amiloride lowers blood pressure and attenuates urine plasminogen activation in patients with treatment-resistant hypertension.
    Oxlund CS, Buhl KB, Jacobsen IA, Hansen MR, Gram J, Henriksen JE, Schousboe K, Tarnow L, Jensen BL.
    J Am Soc Hypertens; 2014 Dec; 8(12):872-81. PubMed ID: 25492830
    [Abstract] [Full Text] [Related]

  • 3. Aprotinin prevents proteolytic epithelial sodium channel (ENaC) activation and volume retention in nephrotic syndrome.
    Bohnert BN, Menacher M, Janessa A, Wörn M, Schork A, Daiminger S, Kalbacher H, Häring HU, Daniel C, Amann K, Sure F, Bertog M, Haerteis S, Korbmacher C, Artunc F.
    Kidney Int; 2018 Jan; 93(1):159-172. PubMed ID: 29042083
    [Abstract] [Full Text] [Related]

  • 4. Plasminogen Deficiency and Amiloride Mitigate Angiotensin II-Induced Hypertension in Type 1 Diabetic Mice Suggesting Effects Through the Epithelial Sodium Channel.
    Andersen H, Hansen MH, Buhl KB, Stæhr M, Friis UG, Enggaard C, Supramaniyam S, Lund IK, Svenningsen P, Hansen PBL, Jensen BL.
    J Am Heart Assoc; 2020 Dec; 9(23):e016387. PubMed ID: 33215566
    [Abstract] [Full Text] [Related]

  • 5. Perspectives on edema in childhood nephrotic syndrome.
    Teoh CW, Robinson LA, Noone D.
    Am J Physiol Renal Physiol; 2015 Oct 01; 309(7):F575-82. PubMed ID: 26290369
    [Abstract] [Full Text] [Related]

  • 6. Nephrotic syndrome is associated with increased plasma K+ concentration, intestinal K+ losses, and attenuated urinary K+ excretion: a study in rats and humans.
    Ydegaard R, Svenningsen P, Bistrup C, Andersen RF, Stubbe J, Buhl KB, Marcussen N, Hinrichs GR, Iraqi H, Zamani R, Dimke H, Jensen BL.
    Am J Physiol Renal Physiol; 2019 Dec 01; 317(6):F1549-F1562. PubMed ID: 31566427
    [Abstract] [Full Text] [Related]

  • 7. Aberrant glomerular filtration of urokinase-type plasminogen activator in nephrotic syndrome leads to amiloride-sensitive plasminogen activation in urine.
    Stæhr M, Buhl KB, Andersen RF, Svenningsen P, Nielsen F, Hinrichs GR, Bistrup C, Jensen BL.
    Am J Physiol Renal Physiol; 2015 Aug 01; 309(3):F235-41. PubMed ID: 25972510
    [Abstract] [Full Text] [Related]

  • 8. Amiloride evokes significant natriuresis and weight loss in kidney transplant recipients with and without albuminuria.
    Hinrichs GR, Nielsen JR, Birn H, Bistrup C, Jensen BL.
    Am J Physiol Renal Physiol; 2023 Oct 01; 325(4):F426-F435. PubMed ID: 37560772
    [Abstract] [Full Text] [Related]

  • 9. Urokinase-type plasminogen activator (uPA) is not essential for epithelial sodium channel (ENaC)-mediated sodium retention in experimental nephrotic syndrome.
    Bohnert BN, Daiminger S, Wörn M, Sure F, Staudner T, Ilyaskin AV, Batbouta F, Janessa A, Schneider JC, Essigke D, Kanse S, Haerteis S, Korbmacher C, Artunc F.
    Acta Physiol (Oxf); 2019 Dec 01; 227(4):e13286. PubMed ID: 31006168
    [Abstract] [Full Text] [Related]

  • 10. Body fluid expansion in acromegaly is related to enhanced epithelial sodium channel (ENaC) activity.
    Kamenicky P, Blanchard A, Frank M, Salenave S, Letierce A, Azizi M, Lombès M, Chanson P.
    J Clin Endocrinol Metab; 2011 Jul 01; 96(7):2127-35. PubMed ID: 21508131
    [Abstract] [Full Text] [Related]

  • 11. Significant natriuretic and antihypertensive action of the epithelial sodium channel blocker amiloride in diabetic patients with and without nephropathy.
    Andersen H, Hansen PB, Bistrup C, Nielsen F, Henriksen JE, Jensen BL.
    J Hypertens; 2016 Aug 01; 34(8):1621-9. PubMed ID: 27214087
    [Abstract] [Full Text] [Related]

  • 12. Registration of amiloride in South Africa: Cutting the Gordian knot.
    Rayner BL, Spence JD, Bryer A, Mpe MT.
    S Afr Med J; 2019 Aug 28; 109(9):632-634. PubMed ID: 31635585
    [Abstract] [Full Text] [Related]

  • 13. Urokinase-type plasminogen activator contributes to amiloride-sensitive sodium retention in nephrotic range glomerular proteinuria in mice.
    Hinrichs GR, Weyer K, Friis UG, Svenningsen P, Lund IK, Nielsen R, Mollet G, Antignac C, Bistrup C, Jensen BL, Birn H.
    Acta Physiol (Oxf); 2019 Dec 28; 227(4):e13362. PubMed ID: 31423748
    [Abstract] [Full Text] [Related]

  • 14. Mechanisms of sodium retention in nephrotic syndrome.
    Hinrichs GR, Jensen BL, Svenningsen P.
    Curr Opin Nephrol Hypertens; 2020 Mar 28; 29(2):207-212. PubMed ID: 31789848
    [Abstract] [Full Text] [Related]

  • 15. Two cases of idiopathic steroid-resistant nephrotic syndrome complicated with thrombotic microangiopathy.
    Nishi K, Sato M, Ogura M, Okutsu M, Ishikura K, Kamei K.
    BMC Nephrol; 2020 Aug 03; 21(1):323. PubMed ID: 32746791
    [Abstract] [Full Text] [Related]

  • 16. Renoprotective effects of thiazides combined with loop diuretics in patients with type 2 diabetic kidney disease.
    Hoshino T, Ookawara S, Miyazawa H, Ito K, Ueda Y, Kaku Y, Hirai K, Mori H, Yoshida I, Tabei K.
    Clin Exp Nephrol; 2015 Apr 03; 19(2):247-53. PubMed ID: 24821289
    [Abstract] [Full Text] [Related]

  • 17. Association of Urinary Plasminogen-Plasmin with Edema and Epithelial Sodium Channel Activation in Patients with Nephrotic Syndrome.
    Chen JL, Wang L, Yao XM, Zang YJ, Wang Y, Li ZJ, Pearce D, Wang H.
    Am J Nephrol; 2019 Apr 03; 50(2):92-104. PubMed ID: 31269481
    [Abstract] [Full Text] [Related]

  • 18. Urinary serine proteases and activation of ENaC in kidney--implications for physiological renal salt handling and hypertensive disorders with albuminuria.
    Svenningsen P, Andersen H, Nielsen LH, Jensen BL.
    Pflugers Arch; 2015 Mar 03; 467(3):531-42. PubMed ID: 25482671
    [Abstract] [Full Text] [Related]

  • 19. Cathepsin B increases ENaC activity leading to hypertension early in nephrotic syndrome.
    Larionov A, Dahlke E, Kunke M, Zanon Rodriguez L, Schiessl IM, Magnin JL, Kern U, Alli AA, Mollet G, Schilling O, Castrop H, Theilig F.
    J Cell Mol Med; 2019 Oct 03; 23(10):6543-6553. PubMed ID: 31368174
    [Abstract] [Full Text] [Related]

  • 20. Potassium-sparing effect of amiloride in a diuretic factorial study in man.
    Schapel GJ, Edwards DG, Robinson J.
    Clin Exp Pharmacol Physiol; 1975 Oct 03; 2(4):277-87. PubMed ID: 1097143
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.